雷替曲塞联合洛铂、吡柔比星治疗中晚期原发性肝癌的疗效及安全性  

Raltitrexed combined with lobaplatin and pirarubicin for the treatment of advanced primary hepatocellular carcinoma:analysis of curative effect and safety

作　　者：张梅[1] 王荣耀[1] 王彩霞[1] 张俊[1] 刘新疆 ZHANG Mei;WANG Rongyao;WANG Caixia;ZHANG Jun;LIU Xinjiang(Affiliated Hospital of Binzhou Medical College,Binzhou,Shandong Province 256603,China)

机构地区：[1]滨州医学院附属医院,山东256603 [2]复旦大学附属浦东医院

出　　处：《介入放射学杂志》2020年第6期600-603,共4页Journal of Interventional Radiology

基　　金：山东省自然科学基金(ZR2016HL43);山东省医药卫生科技发展计划项目(2015WS0479);山东省滨州市科技发展计划项目(2015ZC0305)。

摘　　要：目的探讨应用雷替曲塞联合洛铂、吡柔比星行TACE治疗中晚期原发性肝癌的近期疗效和不良反应。方法选取2016年1月至2018年6月收治的90例无外科切除适应证的原发性肝癌患者,根据治疗方案不同分为观察组(43例)和对照组(47例),观察组给予雷替曲塞联合洛铂、吡柔比星行TACE,对照组给予吡柔比星联合洛铂行TACE治疗。以上治疗每4~6周1次,末次随访时间为2019年3月30日。观察两组治疗的有效率(RR)、疾病控制率(DCR)、无进展生存(PFS)及不良反应。结果观察组和对照组的RR分别为67.44%、40.25%,DCR分别为90.69%、68.08%,中位PFS(mPFS)分别为11个月、8个月,差异均有统计学意义(P均<0.05)。两组患者术后不良反应主要以栓塞后综合征为主,差异无统计学意义(P>0.05)。结论应用雷替曲塞联合洛铂、吡柔比星行TACE,可延长患者生存时间,术后不良反应小,可耐受。Objective To explore the short-term efficacy and adverse reactions of transcatheter arterial chemoembolization(TACE)with combination use of raltitrexed,lobaplatin and pirarubicin in treating advanced primary hepatocellular carcinoma(HCC).Methods A total of 90 HCC patients,who had no indication of surgical resection and were admitted to authors'hospital during the period from January 2016 to June 2018,were enrolled in this study.According to therapeutic scheme,the patients were divided into study group(n=43)and control group(n=47).For the patients of study group TACE by using raltitrexed,lobaplatin and pirarubicin was performed,and for the patients of control group TACE by using lobaplatin and pirarubicin was adopted.TACE procedure was carried out once every 4-6 weeks,the last follow-up date was March 30,2019.The response rate(RR),disease control rate(DCR),progression-free survival(PFS),and adverse reactions were compared between the two groups.Results In the study group and the control group,the RR was 67.44%and 40.25%respectively,the DCR was 90.69%and 68.08%respectively,the median progression-free survival(mPFS)was 11 months and 8 months respectively,and the differences in the above items between the two groups were statistically significant(P<0.05).In both groups,the main adverse reaction was post-embolism syndrome,and the difference between the two groups was not statistically significant(P>0.05).Conclusion For the treatment of advanced HCC,TACE by combination use o f raltitrexed,lobaplatin and pirarubicin can prolong the survival time of patients with only mild and tolerable adverse reactions.

关 键 词：雷替曲塞 原发性肝癌 经肝动脉灌注化疗栓塞术 疗效 

分 类 号：R735.7[医药卫生—肿瘤]